Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PhaseⅠStudy of Irinotecan Hydrochloride Liposome Injection (LY01610) About the Safety, Tolerability, Pharmacokinetics (PK)and Preliminary Efficacy in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

PhaseⅠStudy of Irinotecan Hydrochloride Liposome Injection (LY01610) About the Safety, Tolerability, Pharmacokinetics (PK)and Preliminary Efficacy in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Fluorouracil
  • Indications Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Luye Pharma Group

    • Most Recent Events

    • 25 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2021 The median follow-up duration was 13.1 months (as of data cut-off date: 7 Oct 2020), and all patients had discontinued the study treatment due to progressive disease, adverse event, patient refusal, and deaths.
    • 01 Sep 2021 Status changed to active, no longer recruiting, according to Results published in the Cancer Chemotherapy and Pharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top